PR
CTMX icon

PSP Research’s CytomX Therapeutics CTMX Stock Holding History

PSP Research’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$148K Buy
+39,400
New +$150K 0.08% 71

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

PSP Research's CTMX Position: Q2 2026 in Review

PSP Research opened a new position in CytomX Therapeutics (CTMX) in Q2 2026: 39,400 shares worth $148K. The stake represents 0.08% of the portfolio and ranks #71 among its holdings.

179 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

  • PSP Research held 39,400 shares of CytomX Therapeutics worth $148K as of Q2 2026.
  • CytomX Therapeutics was a new PSP Research position in Q2 2026.
  • CytomX Therapeutics made up 0.08% of PSP Research's portfolio in Q2 2026, its #71 holding.
  • 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on PSP Research's 13F filing for Q2 2026, filed 9 Jul 2026.